AstraZeneca PLC
Deutsche BörseTotal Valuation
AstraZeneca PLC carries a market capitalization of 249.22B, placing it among publicly traded companies globally. Its enterprise value stands at 315.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 249.22B |
| Enterprise Value | 315.45B |
Share Statistics
AstraZeneca PLC currently has 1.55B shares outstanding.
| Shares Outstanding | 1.55B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
AstraZeneca PLC trades at a trailing price-to-earnings ratio of 27.83. The price-to-sales ratio is 4.78, and the price-to-book ratio stands at 28.74.
| PE Ratio | 27.83 |
| PS Ratio | 4.78 |
| PB Ratio | 28.74 |
| P/TBV Ratio | -26.98 |
| P/FCF Ratio | 14.07 |
| P/OCF Ratio | 20.33 |
Enterprise Valuation
On an enterprise value basis, AstraZeneca PLC trades at an EV/EBITDA multiple of 22.04 and an EV/FCF ratio of 14.27. The EV/Sales ratio of 5.22 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.04 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.22 |
| EV / EBITDA | 22.04 |
| EV / EBIT | 22.04 |
| EV / FCF | 14.27 |
Financial Position
AstraZeneca PLC maintains a current ratio of 0.91, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.58, indicating elevated leverage, while an interest coverage ratio of 8.18 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 0.91 |
| Quick Ratio | 0.24 |
| Debt / Equity | 71.58 |
| Debt / EBITDA | 2.37 |
| Interest Coverage | 8.18 |
Financial Efficiency
AstraZeneca PLC posts a return on equity of 150.43 and a return on invested capital of 14.71.
| Return on Equity (ROE) | 150.43 |
| Return on Assets (ROA) | 9.43 |
| Return on Invested Capital (ROIC) | 14.71 |
| Return on Capital Employed (ROCE) | 29.79 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.78 |
Taxes
Over the trailing twelve months, AstraZeneca PLC has paid 2.52B in income taxes, reflecting an effective tax rate of 19.52.
| Income Tax | 2.52B |
| Effective Tax Rate | 19.52 |
Stock Price Statistics
AstraZeneca PLC's stock has gained approximately 11.59722% over the past 52 weeks. The 50-day moving average sits at 159.81, while the 200-day moving average is 142.93.
| Beta (5Y) | N/A |
| 52-Week Price Change | 11.59722% |
| 50-Day Moving Average | 159.81 |
| 200-Day Moving Average | 142.93 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, AstraZeneca PLC generated 60.44B in revenue and converted that into 10.39B in net income, yielding earnings per share of 6.66. EBITDA reached 14.32B, while operating income came in at 14.32B.
| Revenue | 60.44B |
| Gross Profit | 49.37B |
| Operating Income | 14.32B |
| Pretax Income | 12.91B |
| Net Income | 10.39B |
| EBITDA | 14.32B |
| EBIT | 14.32B |
| Earnings Per Share (EPS) | 6.66 |
Balance Sheet
AstraZeneca PLC holds 7.68B in cash and equivalents against 33.92B in total debt, resulting in a net debt position of 24.47B. Total book value stands at 10.06B, with working capital of -2.96B providing operational flexibility.
| Cash & Cash Equivalents | 7.68B |
| Total Debt | 33.92B |
| Net Debt | 24.47B |
| Equity (Book Value) | 10.06B |
| Book Value Per Share | 6.49 |
| Working Capital | -2.96B |
Cash Flow
AstraZeneca PLC produced 14.22B in operating cash flow over the past twelve months. After subtracting -6.47B in capital expenditures, free cash flow totaled 7.75B - equivalent to 5.00 per share.
| Operating Cash Flow | 14.22B |
| Capital Expenditures | -6.47B |
| Free Cash Flow | 7.75B |
| FCF Per Share | 5.00 |
Margins
AstraZeneca PLC operates with a gross margin of 81.68, reflecting its pricing power and cost economics. The operating margin of 23.69 and net profit margin of 17.19 provide insight into operational efficiency.
| Gross Margin | 81.68 |
| Operating Margin | 23.69 |
| Pretax Margin | 21.37 |
| Profit Margin | 17.19 |
| EBITDA Margin | 23.69 |
Dividends & Yields
The company's payout ratio of 47.23 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 3.17 |
| Dividend Yield | N/A |
| Payout Ratio | 47.23 |
| Shareholder Yield | 1.58 |
| FCF Yield | 7.11 |
Stock Splits
AstraZeneca PLC's most recent stock split took place on July 27, 2015 with a 1:2 split ratio.
| Last Split Date | 7/27/2015 |
| Split Ratio | 1:2 |
Scores
AstraZeneca PLC posts an Altman Z-Score of 4.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.71 |